HepQuant is a privately-held, early-stage medical diagnostics company with unique, patented and patent-pending technology for assessing liver function of patients with chronic liver disease. HepQuant technologies, licensed from the University of Colorado Denver (UCD), have been advanced with the intent to profoundly impact the liver disease landscape – including the research, treatment and patient communities – with diagnostic products that are accurate and minimally invasive.

Upcoming Events

• HepQuant will be attending Discovery On Target, “The Industry’s Preeminent Event on Novel Drug Targets” in Boston, Sep. 25-28 (#BostonDOT18). The conference brings together current and emerging “hot” targets, technologies and validation strategies for the development of novel small molecules and biologics. 
• HepQuant will be attending the AASLD Liver Meeting in San Francisco in November. The event will be held Nov. 9 – 13th and is typically attended by more than 9,500 hepatologists and hepatology health professionals from across the nation and around the world.   (More info.) The company will be presenting a poster at the Moscone Center (South Building, Hall C) at 8 a.m. on Sunday, Nov. 11.

Recently Attended

HepQuant’s Chief Business Development Officer Brad Everson and Chief Scientific Officer Dr. Steve Helmke recently attended the 3rd edition of the International Workshop on NASH Biomarkers in Washington, DC.